Wednesday, 14 Nov 2018

You are here

Methotrexate's Low Efficacy in Cutaneous Psoriasis

In a prospective, double-blind, randomized placebo-controlled study, Warren et al. studied the effect of an intensified methotrexate (MTX) in chronic plaque psoriasis and showed MTX to be effective and superior to placebo.  

A total of 120 patients who were MTX-naive adults with active plaque psoriasis patients were randomized to receive 16 weeks of subcutaneous injections of either methotrexate (17.5 mg/wk) or placebo. MTX doses could be escalated to 22.5 mg per week after 8 weeks if patients did not achieve ≥ PASI50% improvement. All patients received folic acid 5 mg per week. 

A PASI 75 response was achieved in 41% of MTX treated but only in 10% of placebo  treated patients (P = 0·0026) by week 16. Subcutaneous methotrexate was generally well tolerated, with no serious adverse events related to this treatment over the 52-week study.

Other analyses and skin biopsies at baseline and week 16 showed MTX clinical effect were mediated by decreases in CD3+ lymphocytes and T helper 17 cell-mediated cytokine transcription.

The authors note that these results are in line with other MTX trials in psoriasis, showing  PASI 75 responses of 36–42% i  3 previous studies using oral methotrexate. Nevertheless, these results are far less than that achieved using biologic therapies, especially the IL-17, IL-23 adn IL-12.23 inhibitors.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

Doubling Down on IL-17 In Psoriatic Arthritis

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

Updates on Psoriatic Arthritis at ACR 2018

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.

Axial Spondylitis Abstracts Roundup

There have been a number of interesting posters and presentations covering the field of axial spondyloarthropathy. I’ve picked out a few points that I found particularly relevant.

Classification Criteria

NK cells and a Potential Role in the Development of PsA vs PsC (Cutaneous Psoriasis)

Human NK cells express multiple receptors that interact with HLA class I molecules which, in turn, suppy peptides that bind HLA-E to form CD94/NKG2A NK receptor ligands. These peptides correspond to -22 to -14 residues in the leader sequences of HLA-A, HLA-B and HLA-C binding to the HLA-E site. Methionine – 21 delivers functional peptides in stark contrast to threonine – 21 which does not.